CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) — Institutional Holders, Q2 2026
13 institutional investment managers reported a CELZ position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $540.3K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
CELZ in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- Hudson Bay Capital ManagementNew · +135,170 sh+$196.0K
- Anson Funds ManagementNew · +105,549 sh+$153.0K
- ARMISTICE CAPITALNew · +42,000 sh+$60.9K
- XTX Topco LtdAdded · +12,299 sh+$17.8K
- Tower Research Capital (TRC)Added · +2,761 sh+$4.0K
Biggest sellers
- GEODE CAPITAL MANAGEMENTTrimmed · -12,491 sh-$18.1K
- SUSQUEHANNA INTERNATIONAL GROUP, LLPSold out · -10,469 sh-$15.2K
- WELLS FARGO & COMPANYSold out · -5,000 sh-$7.3K
- FMRSold out · -250 sh-$362.00
- MORGAN STANLEYTrimmed · -20 sh-$29.00
CELZ 13F holders ranked 1–13 of 13
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Hudson Bay Capital Management#1 · 135,170 sh | 135,170 | $196.0K | <0.01% | New |
| 2 | Anson Funds Management#2 · 105,549 sh | 105,549 | $153.0K | <0.01% | New |
| 3 | ARMISTICE CAPITAL#3 · 42,000 sh | 42,000 | $60.9K | <0.01% | New |
| 4 | XTX Topco Ltd#4 · 26,559 sh | 26,559 | $38.5K | <0.01% | +86.2% |
| 5 | GEODE CAPITAL MANAGEMENT#5 · 25,799 sh | 25,799 | $37.4K | 0.00% | -32.6% |
| 6 | VANGUARD CAPITAL MANAGEMENT#6 · 20,350 sh | 20,350 | $29.5K | 0.00% | 0.0% |
| 7 | VANGUARD FIDUCIARY#7 · 5,518 sh | 5,518 | $8.0K | 0.00% | 0.0% |
| 8 | Tower Research Capital (TRC)#8 · 4,853 sh | 4,853 | $7.0K | <0.01% | +132.0% |
| 9 | Global Retirement Partners#9 · 4,118 sh | 4,118 | $6.0K | <0.01% | — |
| 10 | UBS Group AG#10 · 2,061 sh | 2,061 | $3.0K | 0.00% | New |
| 11 | MORGAN STANLEY#11 · 514 sh | 514 | $745.00 | 0.00% | -3.7% |
| 12 | BARCLAYS PLC#12 · 54 sh | 54 | $78.00 | 0.00% | New |
| 13 | SBI Securities , Ltd.#13 · 43 sh | 43 | $62.00 | — | +4200.0% |
Funds that sold out of CELZ in Q2 2026 (3)
Held CELZ at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP10,469 sh | 10,469 | $21.6K |
| WELLS FARGO & COMPANY5,000 sh | 5,000 | $10.3K |
| FMR250 sh | 250 | $515.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.